In addition, atezolizumab, an IgG1 monoclonal antibody targeting PD-L1, and the anti-VEGFA antibody bevacizumab have produced better outcomes in advanced HCC patients than sorafenib and have become the new standard treatment for patients with unresectable HCC. Here, VEGFA is linked to hepatocellular carcinoma.